


## UBX1325

Cat. No.:	HY-150069
CAS No.:	2271269-01-1
Molecular Formula:	C <sub>53</sub> H <sub>59</sub> ClF <sub>3</sub> N <sub>6</sub> O <sub>10</sub> PS <sub>3</sub>
Molecular Weight:	1159.69
Target:	Bcl-2 Family; Apoptosis
Pathway:	Apoptosis
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (86.23 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	0.8623 mL	4.3115 mL	8.6230 mL
				5 mM	0.1725 mL	0.8623 mL	1.7246 mL
				10 mM	0.0862 mL	0.4311 mL	0.8623 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.16 mM); Clear solution						

### BIOLOGICAL ACTIVITY

Description	UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) <sup>[1]</sup> .
In Vitro	UBX1325 leads to a decrease in the anti-apoptotic Bcl-xL:Bim complex in retina by intravitreal (IVT) injection administration in oxygen induced retinopathy (OIR) C57BL/6 mice model <sup>[1]</sup> . UBX1325 can cause a decrease in retinal vascular permeability and promote retinal neovascularization in streptozotocin (STZ)-induced retinopathy mice model <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA